A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Tarlatamab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Acronyms DeLLphi-308
- Sponsors Amgen
- 17 Oct 2024 Status changed from not yet recruiting to recruiting.
- 01 Oct 2024 New trial record